A Translational Trial on Molecular Markers and Functional Imaging to Predict Response of Preoperative Treatment of Breast Cancer Early
Unknown status
Thomas Hatschek
Phase 2
2008-09-01
Patients with localized primary breast cancer including inflammatory breast cancer suitable
for primary medical treatment and/or regional lymph node metastases receive six cycles of
chemotherapy with epirubicin and docetaxel. Treatment evaluations are performed after the
second, fourth and sixth cycle. In case of SD/PR after the second course, bevacizumab is
added to the combination for the remaining four courses.
Besides standard response evaluation clinically and by mammography and ultrasound, several
functional imaging techniques including MR, CT-PET and contrast-enhanced ultrasound are
investigated. Fresh tumor tissue samples from the primary tumor are collected before start,
after two courses and in connection with surgery. The aim of the trial is to detect
biological factors and functional imaging techniques with the ability to predict response at
an early stage of treatment.
Low-dose Intra-arterial Bevacizumab for Edema and Radiation Necrosis Therapeutic Intervention (LIBERTI)
Completed
University of Kentucky
Phase 2
2016-11-23
To assess the overall safety and efficacy of intra-arterial (IA) bevacizumab for the
treatment of radiation necrosis. A single 2.5 mg/kg dose of bevacizumab will be given
intra-arterially after osmotic blood-brain-barrier disruption.
Low-dose Intra-arterial Bevacizumab for Edema and Radiation Necrosis Therapeutic Intervention (LIBERTI)
Completed
Norton Healthcare
Phase 2
2016-11-23
To assess the overall safety and efficacy of intra-arterial (IA) bevacizumab for the
treatment of radiation necrosis. A single 2.5 mg/kg dose of bevacizumab will be given
intra-arterially after osmotic blood-brain-barrier disruption.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
